GlucoModicum Appoints Peter Gerhardsson to Board of Directors

GlucoModicum has appointed Peter Gerhardsson to its Board of Directors, strengthening the company’s expertise in diabetes care and global CGM commercialization as Sofio advances toward market readiness.

Mr Gerhardsson brings over forty years of experience across the medtech and pharmaceutical industries, including senior leadership roles in diabetes therapies. He previously served as Vice President of International Business Development at Dexcom, where he built and led the company’s global distribution network for continuous glucose monitoring systems. Prior to Dexcom, he held commercial and leadership roles at Novo Nordisk and MiniMed.

Jokke Mäki, Managing Director of GlucoModicum, commented:
“Peter’s deep experience in the CGM field has already been valuable to us, and we are pleased to welcome him to the Board as we continue advancing our needle-free glucose monitoring technology.”

Mr Gerhardsson added that he looks forward to supporting GlucoModicum in bringing new glucose monitoring solutions to people with diabetes.